Figure 1.
Reduced proportion of patients receiving epoetin alfa (EPO), reduced EPO doses, reduced hemoglobin concentrations just preceding and after regulatory changes, and subsequent increase in use of transfusion are shown. Trends in percentage of epoetin alfa (EPO) users (A), median EPO dose per 30 outpatient days (B), median hemoglobin levels (C), and transfusion rates (95% CI) (D) among patients on dialysis, 2005–2012.